Budesonide/formoterol Easyhaler®: a guide to its use in asthma and chronic obstructive pulmonary disease
| Autor: | Gillian M. Keating |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Budesonide
medicine.medical_specialty COPD business.industry Inhaler respiratory system medicine.disease Dry-powder inhaler respiratory tract diseases 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Budesonide/formoterol Maintenance therapy immune system diseases Internal medicine medicine Pharmacology (medical) 030212 general & internal medicine Formoterol business hormones hormone substitutes and hormone antagonists medicine.drug Asthma |
| Zdroj: | Drugs & Therapy Perspectives. 33:95-101 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-017-0378-x |
| Popis: | Budesonide/formoterol Easyhaler® is an easy-to-use, convenient, effective and well tolerated option for the treatment of patients with asthma or chronic obstructive pulmonary disease (COPD). This device-metered dry powder inhaler (DPI) contains both the inhaled corticosteroid budesonide and the long-acting β2-adrenoceptor agonist formoterol. The use of the budesonide/formoterol in a single inhaler is well established as an effective and well tolerated option for the treatment of asthma and COPD. Budesonide/formoterol Easyhaler® is therapeutically equivalent to budesonide/formoterol Turbuhaler®, and is indicated for use as maintenance therapy in adults, adolescents and children aged ≥6 years with asthma, maintenance and reliever therapy in adults with asthma and for the symptomatic treatment of adults with severe COPD and a history of repeated exacerbations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink